Cabaletta Bio downgraded by Wells Fargo with a new price target

12/19/24 7:31:17 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Wells Fargo downgraded Cabaletta Bio from Overweight to Equal Weight and set a new price target of $6.00 from $12.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CABA

Date	Price Target	Rating	Analyst
12/20/2024	$15.00 → $6.00	Outperform → In-line	Evercore ISI
12/19/2024	$12.00 → $6.00	Overweight → Equal Weight	Wells Fargo
10/10/2024	$10.00	Buy	UBS
2/5/2024	$36.00	Buy	Jefferies
11/29/2023	$38.00	Outperform	William Blair
10/24/2023	$40.00	Overweight	Cantor Fitzgerald
10/19/2023	$31.00	Buy	Stifel
9/5/2023	$22.00	Buy	Citigroup